HRAS and neoplasm: Molecular VAF assays were developed for the quantitative detection of RAS variants at single-nucleotide resolution positive for NRAS, HRAS, and KRAS in tumor tissues but not in the adjacent healthy tissue, which were verified by Sanger sequencing (eFigure 1 in Supplement 1).